NCT03263572 - Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemiat(9;22)

Interventions

BIOLOGICAL

Blinatumomab

Given IV

DRUG

Cytarabine

Given intrathecally via spinal tap

DRUG

Methotrexate

Given intrathecally via spinal tap

DRUG

Ponatinib

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston